Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vactosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 known ✓ | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | TGFB1 | P01137 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vactosertib SCHEMBL29352498 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29493095 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL250076 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248684 | 0.94 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL26345807 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL30568127 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248262 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL19492123 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249547 | 0.90 | TGFBR1 (0.81) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249408 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119072542-A | Maturation-promoting agent having ALK 5-inhibiting activity and CDK 8/19-inhibiting activity | 千纸鹤治疗公司 | 2024-12-03 | — | — | CN | claimed |
| CN-117440805-A | Method for treating nonalcoholic steatohepatitis by co-administration of curcumin derivative and TGF-beta receptor inhibitor | 延世大学校原州产学协力团 | 2024-01-23 | — | — | CN | claimed |
| CN-117045651-A | Compositions or methods for treating or preventing corneal endothelial disorders comprising (T) EW-7197 | 学校法人同志社 | 2023-11-14 | — | — | CN | claimed |
| WO-2022270760-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-Β RECEPTOR INHIBITOR | 연세대학교 원주산학협력단 | 2022-12-29 | — | — | WO | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| US-20250333395-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Agomab Spain, S.L.U. (ES) | 2025-10-30 | — | — | US | disclosed |
| US-12409169-B2 | Composition comprising clay mineral complex for prevention, alleviation, and treatment of inflammatory bowel disease, preparation method for composition, and method for alleviation and treatment for inflammatory bowel disease | KOREA INSTITUTE OF GEOSCIENCE AND MINERAL RESOURCES (KR) | 2025-09-09 | — | — | US | disclosed |
| EP-4587477-A2 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | Ohio State Innovation Foundation (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4516894-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-113710278-B | Composition for oral administration comprising controlled release of clay mineral complex, method for preparing same, and controlled release method | 韩国地质资源研究院 | 2025-02-11 | — | — | CN | disclosed |
| US-20250002865-A1 | METHOD FOR PRODUCING ORGANISM, AND METHOD FOR PROMOTING DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED STEM CELLS INTO VASCULAR ENDOTHELIAL CELLS | TOPPAN HOLDINGS INC. (JP) | 2025-01-02 | — | — | US | disclosed |
| WO-2024262844-A1 | NANOPARTICLES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | 한양대학교 산학협력단 | 2024-12-26 | — | — | WO | disclosed |
| WO-2022196927-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROFIBROMATOSIS TYPE 2 SYNDROME | (주)피알지에스앤텍 | 2022-09-22 | — | — | WO | disclosed |
| WO-2022173058-A1 | METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS | 凸版印刷株式会社 | 2022-08-18 | — | — | WO | disclosed |
| WO-2022158571-A1 | HAIR GROWTH STIMULANT | ピアス株式会社 | 2022-07-28 | — | — | WO | disclosed |
| US-20220233602-A1 | GENERATION OF NEURAL STEM CELL LINES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | NOVO NORDISK A/S (DK) | 2022-07-28 | — | — | US | disclosed |
| EP-3994250-A1 | GENERATION OF NEURAL STEM CELL LINES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Novo Nordisk A/S (DK) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | disclosed |
| EP-3969570-A1 | METHODS FOR OBTAINING EYE FIELD PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS | Novo Nordisk A/S (DK) | 2022-03-23 | — | — | EP | disclosed |
| CN-114174497-A | Generation of neural stem cell lines derived from human pluripotent stem cells | 诺和诺德股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409169-B2 | Composition comprising clay mineral complex for prevention, alleviation, and treatment of inflammatory bowel disease, preparation method for composition, and method for alleviation and treatment for inflammatory bowel disease | SLC10A2, SLC10A1, SLC26A3 | TGFBR1 1765/4885MAPK14 2018/4885RIPK2 3732/4885 |
| US-20250333395-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | TGFBR2, TGFBR1, ACVR1 | TGFBR1 2/4885MAPK14 1610/4885RIPK2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.